Juvenile idiopathic arthritis (JIA) is a chronic inflammatory disease and an exclusion diagnosis
that includes all forms of arthritis that persists for more than 6 weeks under the age of 16.
Although there is not yet a cure for JIA, and recent advances in the therapeutic field have created a
more hopeful present and future for the patients. In the past, therapies for JIA have depended on
non-steroidal medication, conventional synthetic disease-modifying antirheumatic drugs and corticosteroids.
However, over the last decades, the advent of biologic therapies in JIA contributed to
the preservation of functional activity, control of pain, avoidance of joint damage, and extra-articular
manifestations. Furthermore, over the last years, international institutions, such as the American
College of Rheumatology, have released recommendations and guidelines for rheumatologists for
optimal JIA management. All the above have revolutionized the treatment of JIA with promising
outcomes. To this end, the relevant literature is reviewed and discussed appropriately.